Marc Duey, Managing Partner
Mr. Duey was the Founder, President and CEO of ProMetrics, LLC, a leading data aggregator and service provider to the specialty pharmaceutical industry for over two decades. ProMetrics is now the Patient Solutions Division of ConcertoAI, a real world data and AI partner to the largest, most ambitious and dynamic oncology firms. Mr. Duey has over three decades of experience in the Pharmaceutical and Biotechnology industries and brings a great deal of commercial business, and product launch experience to portfolio companies. Mr. Duey founded ProMetrics to provide marketing and sales teams with strategic and tactical decision support. Under his direction, the firm has helped launch dozens of biopharma products, serviced over 150 clients, and managed thousands of projects. Seven client biotech firms have been acquired by seven large oncology companies, also clients, for a total transaction value of over $150 billion. Prior to founding ProMetrics, Mr. Duey was founder and President of DuWest Research, an international management consulting firm, with offices on three continents, that specialized in serving the needs of diagnostic and biotechnology firms. Mr. Duey is a member of numerous trade and industry associations and sits on the Board of Directors of several technology companies. He is an adjunct professor at West Chester University in both the Business School and the Pharmaceutical Product Development program (PPD). He serves on the Board of Trustees of International House Philadelphia, and is a member of the Leadership Council of the Wistar Institute. He is an active member of ASCO, AACR and the AAPS.
Investment Philosophy:
The Duce (“Leader”) Fund focuses on biotech and digital health convergence via early stage commitments to emerging firms with intellectual property and platform technology of eventual interest to specialty pharmaceutical manufacturers. Particularly attractive organizations are diving deep into potential therapies for cancer, immunological, and cardiovascular disorders.
➤ LOCATION
2000 Art School Road, Chester Springs PA 19425
☎ CONTACT
MarcDuey@DuceManagement.com
(610) 633-0403
Sample Investments:
ATRIN PHARMACEUTICALS
Atrin Pharmaceuticals is a dynamic clinical-stage biopharmaceutical firm focused on the discovery and development of proprietary oncology medications. Atrin’s bioresearch has led to the development of a portfolio of drug candidates with multiple mechanisms of action. Atrin’s lead program is a novel series of first-in-class, water-soluble, orally bioavailable, highly potent small-molecule inhibitors of ATR. Atrin’s pipeline of unique small molecules allows specific targeting of a broad spectrum of cancers (pancreatic, lung, ovarian, breast and colon) with much higher efficacy and lower toxicity.
Cassian Solutions
Cassian Solutions provides leading patient engagement solutions for specialty pharmacies, PBMs, Health Plans, and Biopharmaceutical firms. The Precision Patient Engagement platform provides highly accessible engagement modalities with machine learning paradigms. Value is delivered via improved adherence and compliance realizing superior patient outcomes, satisfaction, and quality of life at reduced costs.
Felicitex therapeutics
Felicitex Therapeutics is a drug discovery company at the forefront of one of the most promising areas in oncology – quiescent/dormant (sleeping) cancer cells. Felicitex Therapeutics' technology targets quiescent, non-responsive (resistant to therapy) cancer cells with two therapeutically beneficial outcomes - first making quiescent cancer cells vulnerable to conventional treatments and second preventing cancer cells from surviving in the quiescent state for indeterminate period of time and thereby delaying or eliminating cancer recurrence. Felicitex is focused on the development of treatments for the deadliest and most therapy resistant cancers: acute lymphoblastic leukemia (ALL), non-small cell lung, and ovarian
West Chester biomedical ai solutions
West Chester Biomedical AI Solutions (WCBioAI) is a biomedical engineering start-up focused on identifying, developing and commercializing advanced life science technologies, drug delivery platforms and novel devices to move healthcare forward. We partner alongside West Chester University students and entrepreneurs to spearhead new approaches to diagnose, prevent and treat a wide range of medical conditions including COVID-19 and cancer.
TarMeta Biosciences
The TarMeta Drug Discovery Platform offers an approach to the drug discovery process that focuses on efficient and cost-effective pre-clinical drug development. The novel platform is able to generate high-quality drug candidates which are validated against known therapeutic targets of high clinical and commercial interest, while offering potential for a significant return on R&D investments via R&D productivity.
The fundamental core of the platform is the proprietary discovery and characterization of newly generated analogues of commercially attractive investigational and FDA approved medicines. Structural alteration of therapeutic agents can lead to the generation of pharmacologically active derivatives, which may demonstrate improved pharmacological or pharmacokinetic activity as well as decreased toxicity.
Adipoligo Health Sciences
Adipoligo (adipo “fat” and oligo “scarce”) develops advanced novel therapeutics based on siRNA technology addressing unmet needs in cardiovascular disease with a focus on lipid metabolism. Rational design of world class drug candidates is merged with patient engagement expertise to redefine bench-to-bedside process harnessing the power of digital innovation to enhance the value to patients, care team and payer.